UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 12, 2024

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

001-31812

(Commission File Number)

58-2301143 (I.R.S. Employer Identification No.)

210 Main Street West Baudette, Minnesota

Delaware

(State or other jurisdiction of

incorporation)

(Address of principal executive offices)

56623 (Zip Code)

Registrant's telephone number, including area code: (218) 634-3500

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

		Name of each exchange on which
Title of each class	Trading Symbol(s)	registered
Common Stock	ANIP	Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Dere-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02 Results of Operations and Financial Condition

On March 12, 2024, members of ANI Pharmaceuticals, Inc.'s (the "Company") senior management team met with investors at the Leerink Partners Global Biopharma Conference and provided an updated investor presentation. The Company will use the updated presentation in various meetings with investors from time to time. A copy of the presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

Item 7.01	Regulation FD Disclosure
The information in	ncluded under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
Item 9.01	Exhibits
(d) Exhibits	
<u>Exhibit</u> <u>No.</u>	Description
<u>99.1</u>	Investor Presentation_dated March 2024
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)
	Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 12, 2024

ANI PHARMACEUTICALS, INC.

By: Name: Title: /s/ Stephen P. Carey Stephen P. Carey

Senior Vice President Finance and Chief Financial Officer



Disclaimer

To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company's generic pipeline, other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "vill," "expects," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to. Cortrophin GeI is our first rare disease pharmaceutical product; to the extent we are not able to continue to achieve commercialization at levels of market and gaining market share, our business, financial condition, and results of operations will be negatively impacted; our approved products, including Cortrophin GeI, may not achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability; acquisitions and other investments could disrupt our business since and harm our financial position and operating results; the limited number of suppliers or our acive pharmaceutical ingredients could result in lengthy delays in production if we need to our products fee works of lallow us to achieve portitability; acquisitors for any other reason; the ability of our manufacturing patrners to meet our product demands and timelines; our dependence on single source our products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of our manufacturing patrners to meet our product demands and timelines; our deplendence on single sou

More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements, which eras a securities and securities and are based on the Company's current beliefs, assumptions, and expectations. The Company is used as the filings with the securities and forward-looking statements in this presentation speak only as of the date of this presentation and are based on the Company's current beliefs, assumptions, and expectations. The Company is detained to update or review any forward-looking statement, whether as a result of new information future events or otherwise.

Non-GAAP Financial Measures


Non-GAAP Financial Measures
This presentation includes certain non-GAAP financial measures, including Adjusted EBITDA and Adjusted Earnings Per Share (Adjusted EPS), that management reviews to evaluate its business, measure its performance and make
strategic decisions. Management believes that such non-GAAP financial measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as management. Beginning
in the fourth quarter of 2022, ANI no longer excludes expense of In-Process Research & Development or Cotrophin Gel pre-launch charges and sales and marketing expenses from its non-GAAP results. Adjusted mon-GAAP EIITDA
is defined as net income (loss), excluding tax expense or benefit, linterest expenses, (net), depreciation, amortization, the excess of fair value over cost of acquired inventory. non-cash stock-based compensation
expenses, Novilum transaction expenses, contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ANI's results of operations. Adjusted mon-GAAP let income (loss) is defined as net
income (loss), plus the excess of fair value over cost of acquired inventory out, on-cash stock-based compensation expenses, Novilum transaction expenses, depreciation and amortization expenses,
contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ANI's results of operations, less the tax impact of these adjustments calculated using an estimated statutory tax rate. Adjusted
form metrics derived therefrom are financial measures not calculated in accordance with GAAP. And should no the be considered as substitutes for revenue, net income, operating profit, or any other operating performance measures
calculated differently from how management estimates to another expenses, which reduces their calculations are based on the subjective definition to should any the subjective definition on should as the should on the financial measures, such



ANI Pharmaceuticals: Rare Disease and Generics drive robust profitable growth; Established Brands adds strong cash flow

	Key Growth Drivers		Financial Strength	
Serving Patients Improving Lives	Rare Disease business with lead asset Purified Cortrophin Gel	Generics with enhanced R&D capabilities driving new product	\$487M 2023 Revenue	+54% year-over-year revenue growth
	and expansion through M&A	Iaunches; supply reliability Established Brands	140% Adjusted non- GAAP EBITDA growth	\$221M cash ⁽¹⁾ \$119M Cash flow from operations
1. As of 12/31/2023 Parmaceuticals. Inc.				

Q4 2023: Another strong quarter, capping off a record 2023



2024 Guidance


Metric (\$ millions except per share amounts)	Full Year 2024 Guidance	2023 Actuals	Growth vs Prior Year Actuals
Net Revenue (Total Company)	\$520 - \$542	\$487	7 - 11%
Cortrophin Gel Net Revenue	\$170 - \$180	\$112	52 - 61%
Adjusted Non-GAAP EBITDA (1)	\$135 - \$145	\$134	1 - 8%
Adjusted Non-GAAP Diluted EPS (1)	\$4.26 - \$4.67	\$4.71	(10) - (1)%

Adjusted Non-GAAP Diluted EPS guidance reflects a full year of shares outstanding from our May 2023 secondary equity raise.



Control Contro Control Control Control Control Control Control Control Control Co

ANI has consistently delivered high-growth since 2021; strong momentum across all business segments




Revenue growth in 2024 driven by momentum across key growth drivers: Rare Disease and Generics

Business Segment	2023 Actuals (\$ millions)	Full Year 2024 Guidance (\$ millions)	Notes
Rare Disease	\$112	\$170 - \$180	52% - 61% YoY growth
Generics	\$269		High single-digit/low double-digit YoY organic growth
Established Brands, Royalties & Other	\$106		2023 had full-year benefits from supply tailwinds; 2024 guidance includes only tailwinds already seen in Q1
Total Generics, Established Brands, Royalties & Other	\$375	\$350 - \$362	
Total Company	\$487	\$520 - \$542	7% - 11% YoY growth


Note: Figures presented may not total due to rounding.

Profitability driven by gross profit pull-through and leveraging of Rare Disease infrastructure




Rare Disease: ANI's primary growth engine accelerating with lead asset Purified Cortrophin Gel as foundation







Investing in the Cortrophin Gel franchise to drive growth in 2024 and beyond



Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A and in-licensing




Superior R&D capabilities and operational excellence driving growth in Generics




U.S.-based manufacturing footprint; strong GMP track record, <u>including</u> <u>successful recent FDA audits at all three sites</u>

	Baudette, MN 130k sf	Baudette, MN Containment Facility - 47k sf	East Windsor, NJ 120k sf
Facility Overview and Capabilities	 Manufacturing, packaging, warehouse Schedule CII vault & CIII cage space Lab space - R&D/analytical testing Solutions, suspensions, topicals, tablets, capsules, and powder for suspension DEA-licensed for Schedule II controlled substances 	 Manufacturing, packaging, warehouse Low-humidity suite for moisture-sensitive compounds Fully-contained high potency facility for hormone, steroid, and oncolytic products DEA Schedule III capability 	 100K ft² of manufacturing, packaging, lab, warehouse, and administrative space Undergoing 20K ft² expansion that adds 17 new manufacturing suites Solid oral tablets and capsules, liquid suspensions and solutions, powder for oral suspension, controlled substances as well as containment & nano-milling API development & low volume production
Annual Capacity	 Solid Dose ~2.5BN doses Liquid Unit ~23MM doses Liquids ~20MM bottles Powder ~4MM bottles 	 Tablets ~2.5BN doses Capsules ~150MM doses Blisters ~ 45MM doses 	 Tablets & Capsules ~3.0BN doses Packaged Units ~20MM units Liquids ~10MM bottles Powder ~ 2MM bottles ; Semi Solids
GMP	Four FDA inspections since 2013 Latest FDA inspection – November 2022 Results: VAI status	Seven DEA inspections since 2013 Latest FDA inspection – August 2023 Results: VAI status	Seven FDA inspections since 2017, Four DEA inspections since 2016 Latest FDA inspection – January 2024 Results: NAI status (Zero 483s)
Pharmaceuticals, Inc.	© 2024 ANI Pharmaceuticals, Inc.		13

Executive leadership team with proven track records and broad industry expertise



Investment summary





Adjusted non-GAAP EBITDA calculation – 4Q 2023 and 2022

	Three Months Ended [d December 31,	
	 2023	2022	
Net Income(Loss)	\$ 1,155 \$	(4,243)	
Add/(Subtract):			
Interest expense, net	5,746	7,506	
Other expense, net	33	42	
Benefit for income taxes	(208)	(1,485)	
Depreciation and amortization	15, 194	14,484	
Contingent consideration fair value adjustment	1,985	1,624	
Restructuring activities		1,568	
Impact of Canada operations (1)	283	79	
Stock-based compensation	5,621	3,737	
Excess of fair value over cost of acquired inventory	1.000	48	
Novitium transaction expenses	391	(31)	
Adjusted non-GAAP EBITDA	\$ 30,200 \$	23,329	

(1) Impact of Canada operations includes CDMO revenues, cost of sales relating to CDMO revenues, all selling, general, and administrative expenses, and all research and development expenses recorded in Canada in the period presented, exclusive of restructuring activities, stock-based compensation, and depreciation and amorization, which are included within their respective line items above. The adjustment of Canada operations represents revenues, cost of sales and expense that will not recur after the completion of the closure of our Canada operations (complete as of March 31, 2023) and the sale of the facility (on-going as of December 31, 2023). The adjustment of Canada operations does not adjust for revenues, cost of sales, and expense that will recur at our other manufacturing facilities after the transfer of certain manufacturing activities is complete.

Co 2024 ANI Pharmaceuticals, Inc.

Adjusted non-GAAP EBITDA calculation - full year 2023 and 2022

	Twelve Months Ended December 31,		
	-	2023	2022
Net Income(Loss)	\$	18,779 \$	(47,896)
Add/(Subtract):			
Interest expense, net		26,940	28,052
Other expense, net (1)		159	80
Expense (benefit) for income taxes		1,093	(14,769)
Depreciation and amortization		59,791	56,972
Contingent consideration fair value adjustment		1,426	3,756
Intangible asset impairment charge			112
Restructuring activities		1,132	5,679
Impact of Canada operations(2)		2,697	2,740
Stock-based compensation		20,652	14,599
Excess of fair value over cost of acquired inventory		_	5,294
Novitium transaction expenses		1,148	1,244
Adjusted non-GAAP EBITDA	\$	133,817 \$	55,865

 Adjustment to Other expense, net excludes \$750 thousand of income related to the sale of an ANDA during the twelve months ended December 31, 2022.

December 31, 2022.
(2) Impact of Canada operations includes CDMO revenues, cost of sales relating to CDMO revenues, all selling, general, and administrative expenses, and all research and development expenses recorded in Canada in the period presented, exclusive of restructuring activities, stock-based compensation, and depreciation and amortization, which are included within their respective line items above. The adjustment of Canada operations represents revenues, cost of sales and expense that will not recur after the completion of the closure of our Canada operations (complete as of March 31, 2023) and the sale of the facility (on-going as of December 31, 2023). The adjustment of Canada operations does not adjust for revenues, cost of sales, and expense that will recur at our other manufacturing facilities after the transfer of certain manufacturing activities is complete.

Co 2024 ANI Pharmaceuticals, Inc.